Heron Therapeutics Inc (NASDAQ:HRTX) has earned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $53.43.
Several equities analysts recently weighed in on the stock. Cowen restated a “buy” rating on shares of Heron Therapeutics in a report on Thursday, May 9th. Northland Securities restated a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a report on Thursday, May 9th. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. ValuEngine lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a report on Wednesday, May 1st.
NASDAQ HRTX traded down $0.21 during trading hours on Friday, hitting $18.06. The company’s stock had a trading volume of 845,172 shares, compared to its average volume of 1,106,923. Heron Therapeutics has a twelve month low of $16.20 and a twelve month high of $42.90. The firm has a market capitalization of $1.45 billion, a P/E ratio of -7.40 and a beta of 1.45. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The business had revenue of $31.60 million during the quarter, compared to analyst estimates of $28.04 million. During the same quarter in the prior year, the company earned ($1.09) earnings per share. The company’s quarterly revenue was up 172.4% on a year-over-year basis. Sell-side analysts expect that Heron Therapeutics will post -2.47 EPS for the current fiscal year.
In other news, Director Waage Christian bought 1,400 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were bought at an average cost of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the acquisition, the director now owns 1,400 shares in the company, valued at approximately $25,256. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 12.56% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Heron Therapeutics by 5.5% during the first quarter. FMR LLC now owns 8,473,847 shares of the biotechnology company’s stock worth $207,101,000 after acquiring an additional 439,044 shares during the period. Tang Kevin C bought a new position in Heron Therapeutics in the first quarter valued at $952,000. Goldman Sachs Group Inc. grew its position in Heron Therapeutics by 13.6% in the first quarter. Goldman Sachs Group Inc. now owns 791,071 shares of the biotechnology company’s stock valued at $19,333,000 after purchasing an additional 94,665 shares in the last quarter. Oxford Asset Management LLP bought a new position in Heron Therapeutics in the first quarter valued at $1,515,000. Finally, ArrowMark Colorado Holdings LLC grew its position in Heron Therapeutics by 19.9% in the first quarter. ArrowMark Colorado Holdings LLC now owns 2,668,643 shares of the biotechnology company’s stock valued at $65,222,000 after purchasing an additional 443,593 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.